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Summary
Background The global prevalence of X-linked glucose-6-phosphate dehydrogenase (G6PD) deﬁ ciency is thought to be 
a result of selection by malaria, but epidemiological studies have yielded confusing results. We investigated the 
relationships between G6PD deﬁ ciency and both malaria and non-malarial illnesses among children in Kenya.
Methods We did this study in Kiliﬁ  County, Kenya, where the G6PD c.202T allele is the only signiﬁ cant cause of G6PD 
deﬁ ciency. We tested the associations between G6PD deﬁ ciency and severe and complicated Plasmodium falciparum 
malaria through a case-control study of 2220 case and 3940 control children. Cases were children aged younger than 
14 years, who visited the high dependency ward of Kiliﬁ  County Hospital with severe malaria between March 1, 1998, 
and Feb 28, 2010. Controls were children aged between 3–12 months who were born within the same study area 
between August 2006, and September 2010. We assessed the association between G6PD deﬁ ciency and both 
uncomplicated malaria and other common diseases of childhood in a cohort study of 752 children aged younger than 
10 years. Participants of this study were recruited from a representative sample of households within the Ngerenya and 
Chonyi areas of Kiliﬁ  County between Aug 1, 1998, and July 31, 2001. The primary outcome measure for the case-
control study was the odds ratio for hospital admission with severe malaria (computed by logistic regression) while for 
the cohort study it was the incidence rate ratio for uncomplicated malaria and non-malaria illnesses (computed by 
Poisson regression), by G6PD deﬁ ciency category.
Findings 2863 (73%) children in the control group versus 1643 (74%) in the case group had the G6PD normal 
genotype, 639 (16%) versus 306 (14%) were girls heterozygous for G6PD c.202T, and 438 (11%) versus 271 (12%) 
children were either homozygous girls or hemizygous boys. Compared with boys and girls without G6PD deﬁ ciency, 
we found signiﬁ cant protection from severe malaria (odds ratio [OR] 0·82, 95% CI 0·70–0·97; p=0·020) among 
G6PD c.202T heterozygous girls but no evidence for protection among G6PD c.202T hemizygous boys and 
homozygous girls (OR 1·18, 0·99–1·40; p=0·056). Median follow-up for the mild disease cohort study was 
2·24 years (IQR 2·22–2·85). G6PD c.202T had no eﬀ ect on other common diseases of childhood in heterozygous 
girls (incidence rate ratio 0·98, 95% CI 0·86–1·11; p=0·82) or homozygous girls or hemizygous boys (0·93, 
0·82–1·04; p=0·25), with the sole exception of a marginally signiﬁ cant increase in the incidence of helminth 
infections among heterozygous girls.
Interpretation Heterozygous girls might be the driving force for the positive selection of G6PD deﬁ ciency alleles. 
Further studies are needed to deﬁ nitively establish the mechanisms by which G6PD deﬁ ciency confers an advantage 
against malaria in heterozygous individuals. Such studies could lead to the development of new treatments.
Funding Wellcome Trust, UK Medical Research Council, European Union, and Foundation for the National Institutes 
of Health (as part of the Bill & Melinda Gates Grand Challenges in Global Health Initiative).
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Introduction
Glucose-6-phosphate dehydrogenase (G6PD) plays an 
important role in the body’s defence against oxidant 
damage that is particularly important in red blood 
cells.1 The X-chromosome-linked G6PD gene is one of 
the most polymorphic loci of human beings. Almost 
200 allelic variants have been reported, of which around 
40 have reached polymorphic frequencies in multiple 
populations,2 which is widely thought to be a result of 
natural selection by malaria.3 Nevertheless, epidemio-
logical studies investigating this hypothesis have 
yielded confusing results that have not always 
supported this conclusion. A particular controversy has 
surrounded the question of whether protection is 
extended to both boys and girls or is exclusive to female 
carriers.4 We investigated the eﬀ ect of G6PD deﬁ ciency 
on a range of malaria-speciﬁ c and non-malaria 
outcomes in children living in an area in which the 
G6PD c.202T allele is the only signiﬁ cant genetic 
cause.5
Articles
2 www.thelancet.com/haematology   Published online September 23, 2015   http://dx.doi.org/10.1016/S2352-3026(15)00152-0
Methods
Study design and participants
We examined the eﬀ ect of G6PD deﬁ ciency on the risk of 
malaria and other childhood diseases in children living 
within the area served by the Kiliﬁ  Health and 
Demographic Surveillance System in Kenya.6 We did the 
study in two parts: ﬁ rst, we did a case-control study to 
assess the eﬀ ect of G6PD deﬁ ciency on the risk of severe 
Plasmodium falciparum malaria; second, we did a cohort 
study to investigate its eﬀ ect on the risk of uncomplicated 
clinical malaria and other common diseases of childhood.
For the case-control part of the study, we included 
children aged younger than 14 years who were admitted 
with clinical features of severe or complicated 
P falciparum malaria to the high dependency ward of 
Kiliﬁ  County Hospital between March 1, 1998, and 
Feb 28, 2010, as cases. Severe malaria was deﬁ ned by 
blood-ﬁ lm positivity for P falciparum and the patient 
having one or more of the following clinical features: 
prostration (Blantyre Coma Score of 3 or 4), cerebral 
malaria (Blantyre Coma Score of <3), or respiratory 
distress (abnormally deep breathing).7 Cases were further 
classiﬁ ed on the basis of the results of blood tests taken 
on admission to hospital, including base deﬁ cit and 
haemoglobin concentration. Speciﬁ cally, severe malaria 
anaemia was deﬁ ned as a haemoglobin concentration of 
less than 50 g/L in association with respiratory distress. 
Finally, cases were also classiﬁ ed on the basis of their 
hospital inpatient survival status. Controls were children 
aged 3–12 months who were born within the same study 
area between August, 2006, and September, 2010, and 
who were recruited to an ongoing cohort study 
investigating genetic susceptibility to a range of 
childhood diseases.8
The design of the cohort study has been described in 
detail previously.9 In brief, a cohort of children and 
adults of all ages was recruited from a representative 
sample of households within the Ngerenya and Chonyi 
areas of Kiliﬁ  County during August, 1998, and enriched 
thereafter through the recruitment of children born 
subsequently into study homesteads. Participants were 
visited once each week by trained ﬁ eldworkers who 
monitored for febrile episodes through inquiry about 
their health during the preceding interval and by 
Research in context
Evidence before this study
We systematically searched PubMed up to May 22, 2015, for 
original research articles investigating the relationship between 
G6PD deﬁ ciency and malaria, using the term “((glucose-6-
phosphate dehydrogenase deﬁ ciency) AND malaria) OR (G6PD 
AND malaria) NOT “review”[publication type]”. Our search 
returned 564 articles, which we supplemented with secondary 
citations and our personal collections. Most reports focused on 
drug treatment of malaria, particularly the eﬀ ects of primaquine 
and other antimalarial drugs in people with G6PD deﬁ ciency, on 
diagnostic methods for detecting G6PD deﬁ ciency, on G6PD 
deﬁ ciency as a cause of blackwater fever, or were limited to 
descriptions of the prevalence of G6PD deﬁ ciency, and included 
data from studies from diverse regions with very diﬀ erent 
genetic backgrounds and malaria epidemiology. We therefore 
restricted our search to studies done in Africa by the inclusion of 
the additional search term “AND Africa”, returning 157 articles 
that were subjected to further appraisal. These studies used a 
wide range of experimental designs and most had a small 
sample size (<200); however, 34 reports contained at least 
some data regarding the association between G6PD deﬁ ciency 
and malaria from clinical or epidemiological studies since 1960, 
of which eight contained data on asymptomatic parasitaemia, 
15 contained data on uncomplicated malaria, and 16 contained 
data on severe or complicated malaria. These reports reached a 
range of conclusions about the relationship between G6PD 
deﬁ ciency and malaria, including no signiﬁ cant eﬀ ect (six 
reports) or positive or negative associations in various groups 
of males or females (28 reports). Some studies have considered 
heterogeneity at the G6PD locus as a potential explanation for 
the confusing ﬁ ndings from earlier studies, concluding that 
G6PD deﬁ ciency is a balanced polymorphism driven by 
selection for heterozygous females. The wide range of study 
designs, diagnostic approaches, and populations under study 
precluded a formal meta-analysis.
Added value of this study
We investigated the eﬀ ects of G6PD deﬁ ciency on clinical 
malaria phenotypes ranging from asymptomatic parasitaemia 
to strictly deﬁ ned severe malaria, in 7031 children in a malaria-
endemic region of Kenya. We considered allelic heterogeneity at 
the G6PD locus and the possibility of interactions with other 
common malaria-protective red cell polymorphisms. We found 
that the eﬀ ects of G6PD deﬁ ciency were limited to severe 
malaria and malaria-speciﬁ c mortality, adding new weight to 
the conclusion that G6PD deﬁ ciency is a balanced 
polymorphism favouring heterozygous girls.
Implications of the available evidence
Further studies are needed to deﬁ nitively establish the 
mechanisms by which G6PD deﬁ ciency confers an advantage 
against malaria in heterozygous individuals. Such studies could 
lead to the development of new treatments. G6PD deﬁ ciency 
has diﬀ erent eﬀ ects against diﬀ erent subtypes of severe 
malaria, predisposing to severe malarial anaemia but protecting 
against cerebral malaria. Moreover, these subtypes vary with 
malaria transmission intensity and thus between populations 
and over time, meaning that the net evolutionary pressures for 
G6PD deﬁ ciency might be more complex than previously 
appreciated. 
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measuring axillary temperature. If participants reported 
an illness, they were encouraged to attend a dedicated 
outpatient clinic staﬀ ed by study clinicians with access 
to a wide range of quality-assured diagnostic tests. The 
following case deﬁ nitions were applied: malaria was 
deﬁ ned as an episode of fever (axillary temperature 
>37·5°C) in association with a slide positive for blood-
stage asexual P falciparum parasites of any density; non-
malaria fever was deﬁ ned as an episode of fever in a 
child whose slide was negative for P falciparum; upper 
respiratory tract infection was diagnosed in children 
whose principal symptoms were characterised by 
rhinitis or pharyngitis and who had no other features of 
malaria; lower respiratory tract infection was diagnosed 
in children who fulﬁ lled the WHO clinical criteria for 
pneumonia if tests and the subsequent clinical course 
of disease supported this diagnosis; gastroenteritis was 
deﬁ ned as diarrhoea (≥three watery stools per day) with 
or without vomiting (≥three episodes per day); skin 
infection was diagnosed in children who presented with 
dermatological conditions, including scabies, boils, and 
impetigo; helminth infection was diagnosed in children 
who had a history of passing worms of any species; and 
severe anaemia was deﬁ ned as a haemoglobin 
concentration of less than 50 g/L. The present analysis 
focuses on 752 children aged younger than 10 years 
between Aug 1, 1998, and July 31, 2001. Four cross-
sectional surveys were done during this period through 
which the prevalence of P falciparum infection was 
recorded. Asymptomatic malaria parasitaemia was 
deﬁ ned as the presence of a positive P falciparum blood 
ﬁ lm during these cross-sectional surveys in the absence 
of fever or symptoms of clinical illness.
Written informed consent was provided by the parents 
of all study participants and ethical approval for both 
studies was granted by the Kenya Medical Research 
Institute National Ethical Review Committee in Nairobi.
Procedures
Haematological, biochemical, and malaria parasite data 
were derived as previously described.10 We tested for the 
G6PD c.202T allele and the G6PD c.376A allele, which is 
G6PD normal boys and 
girls
G6PD c.202T heterozygous 
girls
G6PD c.202T homozygous 
girls and hemizygous boys
p value
Controls 2863 (73%) 639 (16%) 438 (11%)
Median age (IQR; months) 6·3 (6·2–6·4) 6·4 (6·2–6·6) 6·4 (6·2–6·6) 0·68
Cases 1643 (74%) 306 (14%) 271 (12%)
Median age (IQR; months) 24·7 (23·7–25·6) 23·0 (21·0–25·2) 25·3 (23·1–27·7) 0·31
Mean haemoglobin (95% CI; g/L) 62 (60–63) 62 (58–65) 57 (54–60) 0·0071
Mean MCV (95% CI; fL) 73·2 (72·7–73·6) 75·1 (74·0–76·2) 74·3 (73·1–75·5) 0·0008 
Mean platelets (95% CI; × 10⁶/L) 112 (107–117) 123 (111–136) 134 (120–150) 0·014
Mean base deﬁ cit (mM) 8·5 (8·1–8·9) 8·9 (8·0–9·9) 7·9 (7·0–8·9) 0·13
p values estimated by Kruskal-Wallis rank test. MCV=mean corpuscular volume.
Table 1: Characteristics of patients in the case-control study
All G6PD normal 
boys and girls
G6PD c.202T 
heterozygous 
girls
G6PD c.202T 
homozygous girls 
and hemizygous 
boys
Severe malaria admissions*
Cerebral malaria 1220/2064 (59%) 921/1534 (60%) 168/283 (59%) 131/247 (53%)
Respiratory distress 680/2154 (32%) 510/1601 (32%) 98/294 (33%) 72/259 (28%)
Severe malaria anaemia 683/2220 (31%) 479/1643 (29%) 90/306 (29%) 111/271 (41%)
Other† 374/2220 (17%) 281/1525 (18%) 47/282 (17%) 46/244 (19%)
Inpatient death‡
Overall 256/2220 (12%) 207/1634 (13%) 26/306 (8%) 23/270 (9%)
Cerebral malaria 192/1220 (16%) 155/921 (17%) 19/168 (11 %) 18/131 (14%)
Respiratory distress 117/680 (17%) 97/510 (19%) 11/98 (11%) 9/72 (13%)
Severe malaria anaemia 81/683 (12%) 64/479 (13%) 9/90 (10%) 8/111 (7%)
Other† 21/374 (6%) 16/281 (6%) 2/47 (4%) 3/46 (7%)
Children can appear in more than one category. *Data are missing for some syndromes. †Severe malaria cases without 
any of the other primary characteristics (or when data for these characteristics are missing). ‡Denotes the number of 
deaths among case patients displaying speciﬁ c clinical features.
 Table 2: Distribution of clinical syndromes of severe malaria among cases within the case-control study
G6PD c.202T heterozygous girls G6PD c.202T homozygous girls 
and hemizygous boys
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Admission to hospital
All severe malaria 0·82 (0·70–0·97) 0·020 1·18 (0·99–1·40) 0·056
Cerebral malaria 0·81 (0·67–0·98) 0·037 0·98 (0·78–1·22) 0·88
Respiratory distress 0·84 (0·66–1·07) 0·17 1·00 (0·76–1·32) 0·96
Severe anaemia 0·86 (0·66–1·10) 0·24 1·71 (1·34–2·18) <0·0001
Other severe malaria 0·76 (0·56–1·04) 0·088 1·18 (0·86–1·62) 0·29
Inpatient death
Overall 0·54 (0·35–0·84) 0·0070 0·76 (0·48–1·20) 0·24
Cerebral malaria 0·51 (0·30–0·86) 0·011 0·99 (0·96–1·01) 0·37
Respiratory distress 0·48 (0·25–0·94) 0·032 0·66 (0·33–1·34) 0·26
Severe anaemia 0·58 (0·27–1·23) 0·161 0·78 (0·35–1·74) 0·56
Other severe malaria 0·48 (0·25–0·94) 0·032 0·66 (0·33–1·34) 0·26
Odds ratios are from comparisons of allele frequencies in cases versus controls by logistic regression with 
adjustment for sickle cell trait and α-thalassaemia genotype and ethnic group. Children could contribute data to 
more than one category.
Table 3: Risk of severe malaria and inpatient death in the case-control study
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associated with a minor reduction in G6PD activity,5 on 
the Sequenom MassARRAY iPLEX platform (Agena 
Biosciences, Hamburg, Germany),7 using DNA extracted 
from fresh or frozen samples of whole blood by 
proprietary methods (ABI PRISM, Applied Biosystems, 
CA, USA; or Qiagen DNA Blood Mini Kit, Qiagen, West 
Sussex, UK). Because previous studies have suggested 
the possibility of epistasis with regard to malaria risk, 
between G6PD deﬁ ciency and both the sickle cell trait 
(haemoglobin genotype AS)11 and α thalassaemia,12–14 
samples were also typed at these loci.7,15
Statistical analysis
The primary outcome measure for the case-control study 
was the odds ratio for hospital admission with severe 
malaria whereas for the cohort study it was the incidence 
rate ratio for uncomplicated malaria and non-malaria 
illnesses, by G6PD deﬁ ciency category.
For these analyses, we categorised study participants 
into the three most physiologically meaningful G6PD 
categories based on G6PD c.202T genotypes: (1) 
biochemically normal individuals—ie, boys or girls who 
were either hemizygotes or homozygotes for the wild-
type allele at position 202 of the G6PD gene; (2) G6PD 
c.202T heterozygous girls (who have intermediate G6PD 
activity5); and (3) G6PD c.202T hemizygous boys and 
homozygous girls with G6PD deﬁ ciency. G6PD c.202T 
hemizygous boys and homozygous girls with G6PD 
deﬁ ciency have physiologically identical G6PD activity 
(roughly 12% of normal activity).5,16
We stratiﬁ ed these groups by sex and by genotype at the 
G6PD 376 locus in secondary analyses. We compared 
continuous data using Student’s t test, after normalisation 
by log-transformation where appropriate, whereas we 
compared proportions with the χ² test. We calculated 
odds ratios for severe malaria and its sub-phenotypes in 
the case-control study by comparison of gene frequencies 
among severe malaria cases (both overall and by speciﬁ c 
sub-phenotypes) with those among controls using logistic 
regression. We calculated genotype-speciﬁ c incidence 
rate ratios (IRRs) for malaria and other diseases in the 
cohort study using Poisson regression analysis. We did all 
analyses both with and without adjustment for potential 
confounders. We tested for interactions between 
explanatory variables in both studies using the likelihood 
ratio test. We did all analyses using Stata (version 11.2).
Role of the funding source
None of the funders had a role in the design of the study, 
the collection, analysis, or interpretation of the data, the 
writing of the report, or the decision to submit for 
publication. SU and CMN had full access to the raw data 
and TNW had full access to all of the data and had the 
ﬁ nal responsibility to submit for publication.
Results
The case-control study included 2220 children with severe 
P falciparum malaria and 3940 control participants. 
Table 1 shows the demographic and laboratory 
characteristics of cases and controls, stratiﬁ ed by G6PD 
deﬁ ciency category, while table 2 shows the distribution 
of severe malaria syndromes by sex and G6PD deﬁ ciency. 
The G6PD c.202T allele was in Hardy-Weinberg 
equilibrium in the control population (χ² p=0·32) and 
both cases and controls were well balanced with regard to 
sex (table 1). The proportion of G6PD c.202T heterozygous 
girls was lower among cases than controls (table 1) and 
was associated with a signiﬁ cantly reduced risk of severe 
malaria overall (adjusted odds ratio [OR] 0·82, 95% CI 
Episodes Incidence* IRR (95% CI)† p value
All diagnoses
 G6PD normal boys and girls 5830 5·22 1
 G6PD c.202T heterozygous girls 1314 5·51 0·98 (0·86–1·11) 0·82
 G6PDd boys and girls 1149 4·96 0·93 (0·82–1·04) 0·25
Malaria
 G6PD normal boys and girls 2159 1·93 1
 G6PD c.202T heterozygous girls 508 2·13 1·09 (0·86–1·38) 0·45
 G6PDd boys and girls 440 1·90 0·90 (0·74–1·10) 0·34
Non-malaria fever
 G6PD normal boys and girls 615 0·55 1
 G6PD c.202T heterozygous girls 130 0·54 1·01 (0·80–1·28) 0·91
 G6PDd boys and girls 117 0·50 1·00 (0·77–1·29) 0·97
URTI
 G6PD normal boys and girls 1610 1·44 1
 G6PD c.202T heterozygous girls 379 1·59 1·03 (0·87–1·21) 0·68
 G6PDd boys and girls 290 1·25 0·93 (0·78–1·10) 0·41
LRTI
 G6PD normal boys and girls 636 0·56 1
 G6PD c.202T heterozygous girls 136 0·57 0·77 (0·56–1·05) 0·11
 G6PDd boys and girls 113 0·48 0·99 (0·76–1·30) 0·98
Gastroenteritis
 G6PD normal boys and girls 574 0·51 1
 G6PD c.202T heterozygous girls 113 0·47 0·94 (0·72–1·24) 0·70
 G6PDd boys and girls 113 0·48 1·16 (0·93–1·45) 0·18
Skin infection
 G6PD normal boys and girls 675 0·60 1
 G6PD c.202T heterozygous girls 166 0·69 1·16 (0·85–1·57) 0·33
 G6PDd boys and girls 152 0·65 1·18 (0·89–1·57) 0·22
Helminth infection
 G6PD normal boys and girls 479 0·42 1
 G6PD c.202T heterozygous girls 131 0·54 1·32 (1·00–1·74) 0·048
 G6PDd boys and girls 100 0·43 1·17 (0·88–1·54) 0·26
Severe anaemia
 G6PD normal boys and girls 18 0·01 1
 G6PD c.202T heterozygous girls 3 0·01 0·29 (0·03–2·33) 0·25
 G6PDd boys and girls 3 0·01 0·35 (0·04–2·54) 0·30
Data are for 531 G6PD normal girls and boys (1100 person-years of follow-up), 115 G6PD c.202T heterozygous girls 
(238 person-years of follow-up), and 106 G6PD c.202T homozygous girls or hemizygous boys (231 person-years of 
follow-up). URTI=upper respiratory tract infection. LRTI=lower respiratory tract infection.*Episodes per year of 
follow-up. †Adjusted for age, location, haemoglobin S genotype, and α-thalassaemia genotype.
 Table 4: Incidence of malaria and other common childhood diseases in the mild-disease cohort study
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0·70–0·97; p=0·020) and malaria inpatient death (table 3). 
A subgroup analysis of severe malaria phenotypes 
showed that the most likely protective eﬀ ects were for 
cerebral malaria admission and cerebral malaria death 
(table 3). By contrast, the adjusted odds ratio for severe 
malaria in children with G6PD deﬁ ciency (homozygous 
girls and hemizygous boys for the G6PD c.202T allele) 
was 1·18 (95% CI 0·99–1·40; p=0·056) and the increased 
risk was signiﬁ cant for severe malaria anaemia (table 3). 
This increased risk in severe anaemia was associated with 
lower haemoglobin concentrations in homozygous girls 
and hemizygous boys with G6PD deﬁ ciency and severe 
malaria at the time of hospital admission (table 1). We 
found no signiﬁ cant evidence for an independent eﬀ ect 
of the G6PD c.376A allele on the risk of severe malaria or 
syndrome-speciﬁ c inpatient mortality (appendix p 2–4). 
Moreover, we found no evidence of an interaction 
between G6PD deﬁ ciency category and either sickle cell 
trait (57 cases and 596 controls had sickle cell trait; 
likelihood ratio test 0·19) or α-thalassaemia genotype 
(1026 cases and 1953 controls were heterozygotes for α 
thalassaemia and 264 cases and 637 controls were 
homozygotes; 0·61). Further analyses of the data for male 
and female participants separately made no material 
diﬀ erence to these conclusions (appendix p 5).
Median follow-up for the mild disease cohort study was 
2·24 years (IQR 2·22–2·85). We found no evidence of a 
signiﬁ cant association between G6PD deﬁ ciency category 
and the incidence of uncomplicated P falciparum malaria 
or other common diseases of childhood with the 
exception of a marginally signiﬁ cant increase in the 
incidence of helminth infections in heterozygous girls 
(table 4). We detected no signiﬁ cant diﬀ erences in 
densities of P falciparum parasites during asymptomatic, 
uncomplicated, and severe clinical infections by G6PD 
category (table 5).
Discussion
Through a case-control study done on the coast of Kenya, 
we found that girls who were heterozygotes for the G6PD 
c.202T allelic form of G6PD deﬁ ciency were signiﬁ cantly 
protected from severe and complicated P falciparum 
malaria. Conversely, children with G6PD deﬁ ciency had 
a signiﬁ cantly increased risk of severe malaria anaemia. 
We found no eﬀ ect of G6PD category on parasite 
densities or on the incidence of uncomplicated 
P falciparum malaria or other common diseases of 
childhood either in the same study or in a cohort study of 
children living in the same area. The only exception we 
found was a marginally signiﬁ cant increase in the 
incidence of helminth infections among heterozygous 
girls, an observation which may well represent a chance 
ﬁ nding given the number of comparisons we made.
The global distribution of G6PD deﬁ ciency is thought 
to be a result of natural selection through providing a 
survival advantage against malaria.17 Nevertheless, 
clinicoepidemiological studies have resulted in a 
confusing picture of which, if any, of the alleles 
responsible for G6PD deﬁ ciency protect against malaria, 
against which malaria species, and against which of the 
many clinical manifestations of severe malaria. Whether 
any such advantage is exclusive to heterozygous female 
individuals, or whether it is shared by both sexes equally 
has been especially controversial.4,18 Many factors might 
account for these apparently conﬂ icting conclusions, 
including small sample sizes, variations in study design 
and malaria outcomes, inconsistent deﬁ nitions for G6PD 
deﬁ ciency (including those based on both biochemical 
and genetic methods), allelic heterogeneity at the G6PD 
locus, and epistatic interactions between G6PD 
deﬁ ciency and polymophisms at other loci. In a 
particularly inﬂ uential study done in The Gambia and 
Kenya,19 the authors concluded that both G6PD deﬁ cient 
hemizygous boys and heterozygous girls were protected 
from severe malaria. However, the genetic basis of G6PD 
deﬁ ciency in The Gambia is more complex than 
previously assumed, with the result that this conclusion 
has since been questioned.4,18 The result of these 
conﬂ icting ﬁ ndings is that eﬀ orts to develop new malaria 
treatments on the basis of pathophysiological studies of 
G6PD deﬁ ciency remain somewhat speculative.
We investigated the eﬀ ect of G6PD deﬁ ciency both on a 
range of phenotypes of clinical malaria and on the 
incidence of other common diseases of childhood within 
a single well-characterised population. Based on data 
from our case-control study, the risks of severe malaria 
Asymptomatic Uncomplicated Complicated
 N Mean (95% CI) p value N Mean (95% CI) p value N Mean (95% CI) p value
G6PD normal boys and girls 446 1430 (1207–1695) .. 1152 23 024 (20 283–26 136) .. 1643 41 464 (36 781–46 742) ..
G6PD c.202T heterozygous girls 88 1195 (830–1722) .. 246 20 051 (15 117–26 595) .. 306 41 157 (31 184–54 319) ..
G6PD c.202T homozygous girls and 
hemizygous boys
113 1703 (1185–2448) 0·33 251 20 031 (15 144–26 495) 0·56 271 35 063 (26 432–46 512) 0·39
We measured asymptomatic parasite densities through cross-sectional surveys of members of the mild-disease cohort study (data collected from 321 G6PD normal girls and boys, 81 G6PD c.202T heterozygous 
girls, and 81 G6PD c.202T homozygous girls or hemizygous boys). We assessed densities during uncomplicated malaria infections recorded within the mild-disease cohort study (data contributed by 409 G6PD 
normal girls and boys [856 person-years of follow-up], 87 G6PD c.202T heterozygous girls [187 person-years of follow-up], and 85 G6PD c.202T homozygous girls or hemizygous boys [180 person-years of 
follow-up]). We assessed densities during complicated malaria episodes in severe malaria cases within the case–control study. We used the Kruskal-Wallis rank test to calculate p values to compare the three 
groups within each category.
 Table 5: Plasmodium falciparum densities in the case-control and mild-disease cohort studies
See Online for appendix
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and within-hospital death among G6PD c.202T 
heterozygous girls were signiﬁ cantly lower than in G6PD 
normal children. Conversely, the risks of severe malarial 
anaemia in G6PD c.202T hemizygous boys and 
homozygous girls with G6PD deﬁ ciency were 
signiﬁ cantly higher. Data from our cohort study showed 
no eﬀ ect of G6PD category on the prevalence or incidence 
of either uncomplicated malaria or of any other common 
childhood disease, with the sole exception of a marginally 
signiﬁ cant increase in the incidence of helminth 
infections among heterozygous girls. Taken together, our 
data support the previous conclusion that G6PD 
deﬁ ciency is a balanced polymorphism conferring a 
selection advantage in heterozygous girls at the expense 
of a ﬁ tness disadvantage in those with G6PD deﬁ ciency.4,18
Although our conclusions support the results of some 
previous clinical studies,20–24 they do not concur with 
others that have found either no association between 
G6PD deﬁ ciency and various phenotypes of P falciparum 
infection,25,26 or evidence for protection in various 
combinations of males and females19,27,28 in several other 
settings. Moreover, P falciparum is the only signiﬁ cant 
cause of clinical malaria in Kenya; therefore, we were 
unable to investigate the hypothesis that G6PD deﬁ ciency 
might protect against Plasmodium vivax malaria.29 
Nevertheless, we believe that our study, which to the best 
of our knowledge is the largest and most comprehensive 
yet reported from a single site, has several advantages 
over many previous studies.
First, we characterised participants on the basis of 
G6PD genotype as opposed to G6PD phenotype. The 
high degree of overlap in enzyme activity between the 
various haplotypic groups5,30 and the fact that almost all 
the allelic sites in the common haplotypes have no 
known or measurable eﬀ ect on G6PD activity makes it 
impossible to predict G6PD genotypes from data for 
G6PD enzyme activity alone. This limitation is 
particularly relevant for polymorphisms that confer 
milder phenotypes, such as the common African G6PD 
c.202T and G6PD c.376A polymorphisms in which, for 
example, there is no overlap in G6PD activity between 
male hemizygotes with the G6PD c.202T allele and those 
with the G6PD c.376A allele, the latter being essentially 
G6PD normal.31 For this reason, with one exception,20 
phenotypic studies have classiﬁ ed participants as normal 
or deﬁ cient on the basis of arbitrary break points that 
may or may not be biologically meaningful. Although 
only four alleles have been found to be associated with 
G6PD deﬁ ciency in African populations (G6PD c.202T, 
G6PD c.542A, G6PD c.680T, and G6PD c.968C32,33), 
studies have not been exhaustive and other alleles might 
remain to be discovered. As such, we believe that a 
genetic approach to the classiﬁ cation of G6PD deﬁ ciency 
is likely to yield more interpretable results.
A second strength of our study is that, by contrast with 
most previous studies in which participants have been 
selected on the basis of G6PD genotype, we minimised 
the possibility of misclassiﬁ cation of G6PD deﬁ ciency 
through earlier studies32 in which we established that the 
G6PD c.202T allele is the only substantial determinant 
of G6PD deﬁ ciency in our study population.5 Interpreting 
data from studies done in areas in which G6PD activity 
is aﬀ ected by multiple polymorphisms is much more 
challenging. Under such circumstances, unrecognised 
allelic heterogeneity can lead to confounding through 
misclassiﬁ cation of participants as G6PD normal, which 
might have led to misleading conclusions in previous 
studies done in west Africa, where there is greater 
diversity at the G6PD locus.4,18 Even when recognised, 
allelic heterogeneity can make the interpretation of 
epidemiological studies more diﬃ  cult because diﬀ erent 
mutations can have widely diﬀ ering phenotypic eﬀ ects1 
that can make classiﬁ cations based on combined 
groupings somewhat hypothetical. The situation is 
further complicated by the fact that G6PD deﬁ ciency 
seems to have two opposing actions on severe malaria, 
decreasing the risk of cerebral malaria but increasing 
the risk of severe malarial anaemia, as shown in a large 
multicentre study that included some of the data 
reported here.7 As a consequence, the overall eﬀ ect of 
G6PD deﬁ ciency might depend on the relative 
frequencies of cerebral malaria and severe malaria 
anaemia, which is related to the intensity of malaria 
transmission and will therefore vary over time and 
between diﬀ erent epidemiological settings. Finally, the 
alternative approach of analysing studies by individual 
genotypes, stratiﬁ ed by sex, leads to diﬃ  culties with 
analytical power, as exempliﬁ ed by a study done in The 
Gambia, despite using a large sample.32
Unlike most previous studies, we excluded the 
possibility of confounding by two other malaria-
protective polymorphisms—sickle cell trait and 
α thalassaemia—both of which are common in our study 
population. A negative epistatic interaction between 
sickle cell trait and G6PD deﬁ ciency has been reported 
previously in Mali,11 whereas the possibility of epistasis 
with the thalassaemias has been suggested by population 
genetic studies in Sardinia12,13 and Saudi Arabia.14 
Nevertheless, data from our study show that in Kiliﬁ , the 
eﬀ ect of G6PD deﬁ ciency on malaria is independent 
from both these polymorphisms, and our ﬁ ndings are 
robust to adjustments for these independent eﬀ ects. 
Finally, we studied the eﬀ ect of G6PD deﬁ ciency on both 
malaria-speciﬁ c and non-malaria-speciﬁ c outcomes 
within a single well-characterised population, and found 
no evidence for a signiﬁ cant eﬀ ect of G6PD deﬁ ciency 
category on susceptibility to uncomplicated clinical 
malaria or to other common diseases of childhood.
Despite having arisen thousands of years ago, there 
remain no examples of populations in which any of the 
many G6PD deﬁ ciency mutations have been selected to 
the point of ﬁ xation,4 suggesting that either their selective 
advantage is very small or that their rising frequency has 
been checked by balancing selection. Our ﬁ ndings support 
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the latter hypothesis: that frequencies of the G6PD c.202T 
allele in Kiliﬁ  are a result that frequencies of the G6PD 
c.202T allele in Kiliﬁ  are a result of historic selection for 
heterozygous girls through a survival advantage against 
severe malaria balanced by the increased loss from severe 
malaria anaemia of both G6PD c.202T hemizygous boys 
and homozygous girls with G6PD deﬁ ciency. The G6PD 
c.202T allele is associated with such a mild phenotype that 
even hemizygous boys and homozygous girls retain 12% 
of normal G6PD activity5,34 and, as a result, are rarely 
aﬀ ected by the more severe manifestations of G6PD 
deﬁ ciency, with the exception of challenge by powerful 
oxidants such as dapsone.35 We suggest, therefore, that 
historically, malaria alone may be suﬃ  cient to explain 
balancing selection against G6PD c.202T hemizygous 
boys and homozygous girls.
Our study has several limitations of which perhaps the 
most important relates to the fact that, to a large extent, 
our study design was opportunistic and capitalised on 
the existence of data and samples collected for other 
purposes. As a result, participants were recruited over a 
long period during which the transmission of malaria 
within the study area declined substantially.36 Moreover, 
our control participants were substantially younger than 
case participants. However, we believe that such design 
limitations would be more likely to mitigate against our 
results than favour them because any selection for G6PD 
deﬁ ciency by malaria would result in a rising prevalence 
by age and over time, which would have the eﬀ ect of 
enhancing rather than reducing the diﬀ erences that we 
have recorded.
Second, the lack of statistical evidence for an eﬀ ect of 
G6PD deﬁ ciency on the incidence of uncomplicated 
malaria or other childhood diseases might simply be a 
result of a lack of statistical power, either because the 
study or the eﬀ ect sizes were too small. Furthermore, 
being purely epidemiological, our study can provide no 
deﬁ nitive insights into the mechanisms by which G6PD 
deﬁ ciency confers malaria protection. Nevertheless, the 
fact that we found no meaningful diﬀ erence in parasite 
densities between G6PD deﬁ ciency categories across the 
full range of P falciparum infections does not, on the face 
of it, support most hypotheses advanced to date. Most 
have invoked the reduced ability of erythrocytes of people 
with G6PD deﬁ ciency to cope with the oxidant stresses 
that accompany P falciparum infection, and suggest that 
this eﬀ ect might either reduce the ability of parasites to 
grow and develop or precipitate their early removal once 
infected.3,37 Under either of these scenarios, we would 
anticipate that children with G6PD deﬁ ciency would 
have lower parasite densities during clinical infections in 
vivo. Although reduced densities were noted in several 
early studies, which are often cited in support of existing 
mechanistic hypotheses,20,21,38 more recent studies have 
been inconsistent, with some showing lower densities in 
various subgroups,39,40 some ﬁ nding none,28,41 and most 
suﬀ ering from low statistical power. Therefore, it can be 
said only that the mechanism of protection remains 
unproven and is worthy of additional research.
Why G6PD deﬁ ciency should be associated with an 
increased risk of severe malaria anaemia is also open to 
speculation; however, malaria parasites exert oxidant 
stress on red cells42 and excessive oxidant stress causes 
acute haemolysis in people with G6PD deﬁ ciency,1 
meaning that the excess risk of anaemia during the course 
of malaria infections in children with G6PD deﬁ ciency 
makes biological sense. Similarly, the selective advantage 
for heterozygous girls might be explained by the fact that, 
as a result of random inactivation of the X chromosome, 
they beneﬁ t from two roughly equal populations of red 
blood cells—one fully deﬁ cient and the other fully non-
deﬁ cient.20 This raises the possibility that such children 
enjoy the best of both worlds: roughly half of their red 
blood cells being protected by G6PD deﬁ ciency through a 
mechanism that remains incompletely understood, while 
the remaining half buﬀ er against an overwhelming drop 
in haemoglobin that can complicate malaria more often in 
fully deﬁ cient individuals. Although it has been suggested 
that more subtle changes in G6PD structure or function, 
including that associated with the G6PD c.376A allele, 
might also confer protection against malaria,24 this 
possibility is not supported by data from this study, which 
show that the eﬀ ects of G6PD on malaria risk were 
exclusively related to the G6PD c.202T mutation.
In conclusion, more than half a century since the 
protective eﬀ ect of G6PD deﬁ ciency against malaria was 
ﬁ rst proposed, the clinical epidemiology of malaria in 
children with G6PD deﬁ ciency has remained confusing. 
Our study provides strong support for the conclusion 
that the G6PD c.202T allele has reached its present 
frequencies in much of sub-Saharan Africa through 
positive selection for heterozygous girls through a 
mechanism mediated by malaria. We hope that this 
growing consensus will lead to a renewed drive to 
determine the mechanisms involved and to turn this 
knowledge to new approaches to malaria treatment.
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